Esperion Therapeutics, Inc. (ESPR)

Data as of Jul 13, 2026, from SEC Form 4 filings.

No open-market insider trades (90d)Watch ESPR

See up to 3 months of ESPR. The 7-day demo opens the 1M and 3M ranges and puts ESPR on your watchlist.

Latest ESPR insider trades

Benjamin Looker - Officer
Open-market sale$37K
Jun 17, 2026
Sheldon L. Koenig - Officer
Open-market sale$169K

About Esperion Therapeutics, Inc. (ESPR)

The SEC lists Esperion Therapeutics, Inc. under CIK 0001434868, in pharmaceutical preparations. We track it alongside the rest of the Health Care sector.

Sector: Health Care

SEC filings for ESPR on EDGAR

ESPR Form 4 activity by transaction type, last 90 days

No Form 4 activity for ESPR in the last 90 days.

ESPR insider transactions (Form 4)

41 Form 4 filings on record, the earliest from Oct 18, 2024, newest first. Filing history page 1 of 2.

Date	Insider	Transaction	Security	Shares	Price	Value
Jul 13, 2026	Robert E. Hoffman - Director	Derivative	Common Stock	85,153^{footnote F2,F3}	-^{footnote F2,F3}	-
Jul 13, 2026	Robert E. Hoffman - Director	Derivative	Stock Option (right to buy)	40,000	-^{footnote F4}	-
Jul 13, 2026	Robert E. Hoffman - Director	Derivative	Stock Option (right to buy)	7,040	-^{footnote F4}	-
Footnote F2 (price, shares): At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual… Full note on SEC EDGAR Footnote F3 (price, shares): Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with… Full note on SEC EDGAR Footnote F4 (price): At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such… Full note on SEC EDGAR
Jul 13, 2026	J. Martin Carroll - Director	Derivative	Common Stock	177,523^{footnote F2,F3}	-^{footnote F2,F3}	-
Jul 13, 2026	J. Martin Carroll - Director	Derivative	Stock Option (right to buy)	21,000	-^{footnote F4}	-
Jul 13, 2026	J. Martin Carroll - Director	Derivative	Stock Option (right to buy)	32,500	-^{footnote F4}	-
Jul 13, 2026	J. Martin Carroll - Director	Derivative	Stock Option (right to buy)	44,000	-^{footnote F4}	-
Footnote F2 (price, shares): At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual… Full note on SEC EDGAR Footnote F3 (price, shares): Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with… Full note on SEC EDGAR Footnote F4 (price): At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such… Full note on SEC EDGAR
Jul 13, 2026	Jay Shepard - Director	Derivative	Common Stock	164,472^{footnote F2,F3}	-^{footnote F2,F3}	-
Jul 13, 2026	Jay Shepard - Director	Derivative	Stock Option (right to buy)	21,000	-^{footnote F4}	-
Jul 13, 2026	Jay Shepard - Director	Derivative	Stock Option (right to buy)	32,500	-^{footnote F4}	-
Jul 13, 2026	Jay Shepard - Director	Derivative	Stock Option (right to buy)	44,000	-^{footnote F4}	-
Footnote F2 (price, shares): At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual… Full note on SEC EDGAR Footnote F3 (price, shares): Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with… Full note on SEC EDGAR Footnote F4 (price): At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such… Full note on SEC EDGAR
Jul 13, 2026	Seth H. Z. Fischer - Director	Derivative	Common Stock	141,023^{footnote F2,F3}	-^{footnote F2,F3}	-
Jul 13, 2026	Seth H. Z. Fischer - Director	Derivative	Stock Option (right to buy)	21,000	-^{footnote F4}	-
Jul 13, 2026	Seth H. Z. Fischer - Director	Derivative	Stock Option (right to buy)	32,500	-^{footnote F4}	-
Jul 13, 2026	Seth H. Z. Fischer - Director	Derivative	Stock Option (right to buy)	44,000	-^{footnote F4}	-
Footnote F2 (price, shares): At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual… Full note on SEC EDGAR Footnote F3 (price, shares): Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with… Full note on SEC EDGAR Footnote F4 (price): At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such… Full note on SEC EDGAR
Jul 13, 2026	John Craig Thompson - Director	Derivative	Common Stock	79,873^{footnote F2,F3}	-^{footnote F2,F3}	-
Jul 13, 2026	John Craig Thompson - Director	Derivative	Stock Option (right to buy)	40,000	-^{footnote F4}	-
Footnote F2 (price, shares): At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual… Full note on SEC EDGAR Footnote F3 (price, shares): Consists of 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive… Full note on SEC EDGAR Footnote F4 (price): At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such… Full note on SEC EDGAR
Jul 13, 2026	John B. Harlow Jr. - Officer	Derivative	Common Stock	424,536^{footnote F2,F3}	-^{footnote F2,F3}	-
Footnote F2 (price, shares): At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual… Full note on SEC EDGAR Footnote F3 (price, shares): Consists of 424,536 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive… Full note on SEC EDGAR
Jul 13, 2026	Benjamin Looker - Officer	Derivative	Common Stock	667,524^{footnote F2,F3}	-^{footnote F2,F3}	-
Jul 13, 2026	Benjamin Looker - Officer	Derivative	Stock Option (right to buy)	150,000	-^{footnote F4}	-
Jul 13, 2026	Benjamin Looker - Officer	Derivative	Stock Option (right to buy)	201,000	-^{footnote F4}	-
Jul 13, 2026	Benjamin Looker - Officer	Derivative	Stock Option (right to buy)	269,230	-^{footnote F4}	-
Footnote F2 (price, shares): At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual… Full note on SEC EDGAR Footnote F3 (price, shares): Includes 483,635 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with… Full note on SEC EDGAR Footnote F4 (price): At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such… Full note on SEC EDGAR
Jul 13, 2026	Benjamin Halladay - Officer	Derivative	Common Stock	705,410^{footnote F2,F3,F4}	-^{footnote F2,F3}	-
Jul 13, 2026	Benjamin Halladay - Officer	Derivative	Stock Option (right to buy)	200,000	-^{footnote F5}	-
Jul 13, 2026	Benjamin Halladay - Officer	Derivative	Stock Option (right to buy)	213,000	-^{footnote F5}	-
Jul 13, 2026	Benjamin Halladay - Officer	Derivative	Stock Option (right to buy)	221,270	-^{footnote F5}	-
Footnote F2 (price, shares): At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual… Full note on SEC EDGAR Footnote F3 (price, shares): Includes 477,191 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with… Full note on SEC EDGAR Footnote F4 (shares): Includes 2,581 shares recently acquired in Esperion's Employee Stock Purchase Plan. Footnote F5 (price): At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such… Full note on SEC EDGAR
Jul 13, 2026	Sheldon L. Koenig - Officer	Derivative	Common Stock	2,121,094^{footnote F2,F3,F4}	-^{footnote F2,F3}	-
Jul 13, 2026	Sheldon L. Koenig - Officer	Derivative	Stock Option (right to buy)	642,000	-^{footnote F5}	-
Jul 13, 2026	Sheldon L. Koenig - Officer	Derivative	Stock Option (right to buy	753,000	-^{footnote F5}	-
Jul 13, 2026	Sheldon L. Koenig - Officer	Derivative	Stock Option (right to buy)	647,460	-^{footnote F5}	-
Footnote F2 (price, shares): At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual… Full note on SEC EDGAR Footnote F3 (price, shares): Includes 1,474,344 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive… Full note on SEC EDGAR Footnote F4 (shares): Includes 1,983 shares recently acquired in Esperion's Employee Stock Purchase Plan. Footnote F5 (price): At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such… Full note on SEC EDGAR
Jun 17, 2026	Benjamin Looker - Officer	Open-market sale	Common Stock	11,824^{footnote F1}	$3.16	$37K
Footnote F1 (shares): Shares were sold to satisfy tax obligation on vested shares of restricted stock units.
Jun 17, 2026	Sheldon L. Koenig - Officer	Open-market sale	Common Stock	53,588^{footnote F1}	$3.16	$169K
Footnote F1 (shares): Shares were sold to satisfy tax obligation on vested shares of restricted stock units.
Jun 17, 2026	Benjamin Halladay - Officer	Open-market sale	Common Stock	10,773^{footnote F1}	$3.16	$34K
Footnote F1 (shares): Shares were sold to satisfy tax obligation on vested shares of restricted stock units.
May 28, 2026	John Craig Thompson - Director	Grant or award	Common Stock	79,873^{footnote F1}	$0.00	-
Footnote F1 (shares): The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026.
May 28, 2026	Jay Shepard - Director	Grant or award	Common Stock	79,873^{footnote F1}	$0.00	-
Footnote F1 (shares): The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026.
May 28, 2026	Robert E. Hoffman - Director	Grant or award	Common Stock	79,873^{footnote F1}	$0.00	-
Footnote F1 (shares): The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026.
May 28, 2026	Seth H. Z. Fischer - Director	Grant or award	Common Stock	79,873^{footnote F1}	$0.00	-
Footnote F1 (shares): The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026.
May 28, 2026	J. Martin Carroll - Director	Grant or award	Common Stock	79,873^{footnote F1}	$0.00	-
Footnote F1 (shares): The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026.
Mar 17, 2026	Benjamin Looker - Officer	Open-market sale	Common Stock	5,708^{footnote F1}	$2.70	$15K
Footnote F1 (shares): Shares were sold to satisfy tax obligation on vested shares of restricted stock units.
Mar 17, 2026	Sheldon L. Koenig - Officer	Open-market sale	Common Stock	25,578^{footnote F1}	$2.72	$70K
Footnote F1 (shares): Shares were sold to satisfy tax obligation on vested shares of restricted stock units.
Mar 17, 2026	Benjamin Halladay - Officer	Open-market sale	Common Stock	6,424^{footnote F1}	$2.71	$17K
Footnote F1 (shares): Shares were sold to satisfy tax obligation on vested shares of restricted stock units.
Mar 13, 2026	Benjamin Looker - Officer	Grant or award	Common Stock	300,840^{footnote F1}	$0.00	-
Mar 13, 2026	Benjamin Looker - Officer	Grant or award	Stock Option (right to buy)	269,230	$0.00	-
Footnote F1 (shares): Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2026.
Mar 13, 2026	Sheldon L. Koenig - Officer	Grant or award	Common Stock	723,760^{footnote F1}	$0.00	-
Mar 13, 2026	Sheldon L. Koenig - Officer	Grant or award	Stock Option (right to buy)	647,460	$0.00	-
Footnote F1 (shares): Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2026.
Mar 13, 2026	Benjamin Halladay - Officer	Grant or award	Common Stock	247,430^{footnote F1}	$0.00	-
Mar 13, 2026	Benjamin Halladay - Officer	Grant or award	Stock Option (right to buy)	221,270	$0.00	-
Footnote F1 (shares): Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2026.
Jan 20, 2026	Benjamin Looker - Officer	Open-market sale	Common Stock	1,689^{footnote F1}	$2.88	$5K
Footnote F1 (shares): Shares were sold to satisfy tax obligation on vested shares of restricted stock units.
Oct 17, 2025	Benjamin Looker - Officer	Open-market sale	Common Stock	1,248^{footnote F1}	$2.62	$3K
Footnote F1 (shares): Shares were sold to satisfy tax obligation on vested shares of restricted stock units.
Sep 17, 2025	Benjamin Halladay - Officer	Open-market sale	Common Stock	7,046	$2.81	$20K
Sep 17, 2025	Benjamin Looker - Officer	Open-market sale	Common Stock	6,267	$2.80	$18K
Sep 17, 2025	Sheldon L. Koenig - Officer	Open-market sale	Common Stock	28,427	$2.79	$79K
Jul 17, 2025	Benjamin Looker - Officer	Open-market sale	Common Stock	1,304	$1.13	$1K
Jul 17, 2025	Benjamin Halladay - Officer	Open-market sale	Common Stock	11	$1.12	$12

Recent ESPR Form 8-K filings

Read ESPR company news

Jul 13, 2026Item 1.01, 1.02, 2.01, 2.03, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01

Read the filing on SEC EDGAR

Jul 8, 2026Item 5.07

Read the filing on SEC EDGAR

Jun 18, 2026Item 9.01

Read the filing on SEC EDGAR

Jun 16, 2026Item 8.01

Recent ESPR Form 144 notices of proposed sale

An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.

Filed	Filer	Relationship	Shares	Market value	Notice
Jun 17, 2026	-	-	-	-	View on EDGAR
Jun 17, 2026	-	-	-	-

ESPR insider trading FAQ

What is the latest insider trade for ESPR?

Esperion Therapeutics, Inc. (ESPR) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-07-13. The full record for ESPR runs to 41 Form 4 filings, the earliest from 2024-10-18. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.

How many insiders are buying ESPR stock?

No insider purchases of ESPR were filed in the last 90 days.

How many insiders are selling ESPR stock?

No insider sales of ESPR were filed in the last 90 days. 18 sales are on record for this company.

Where can I see ESPR SEC filings (Form 4, 10-K, 10-Q, 8-K)?

This page collects ESPR Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.

More Health Care companies with insider activity

Recent insider filings

The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.

Jul 13, 2026 - Robert E. Hoffman view on EDGAR
Jul 13, 2026 - J. Martin Carroll view on EDGAR
Jul 13, 2026 - Jay Shepard view on EDGAR
Jul 13, 2026 - Seth H. Z. Fischer view on EDGAR
Jul 13, 2026 - John Craig Thompson view on EDGAR
Jul 13, 2026 - John B. Harlow Jr. view on EDGAR
Jul 13, 2026 - Benjamin Looker view on EDGAR
Jul 13, 2026 - Benjamin Halladay view on EDGAR
Jul 13, 2026 - Sheldon L. Koenig view on EDGAR

Related companies with recent insider activity

Learn more

What the Form 4 transaction codes mean: Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
Form 144 vs Form 4: A Form 144 announces a planned sale; the Form 4 reports it after it happens.
Insider activity in Health Care: Where ESPR's peers are being bought and sold.
Every recent Form 4: The market-wide feed, updated as filings arrive from SEC EDGAR.

Follow ESPR with a 7-day demo

ESPR on your watchlist
Every ESPR Form 4 filing on record
Up to 3 months of ESPR price history
The daily trading plan of ranked insider buys, on a delay, with the plan archive

Start 7-day demoCard required. Your card is never charged for the demo.

Date

Insider

Transaction

Security

Price

Value

Jul 13, 2026

Robert E. Hoffman - Director

Derivative

Common Stock

85,153^{footnote F2,F3}

-^{footnote F2,F3}

Jul 13, 2026

Robert E. Hoffman - Director

Derivative

Stock Option (right to buy)

40,000

-^{footnote F4}

Jul 13, 2026

Robert E. Hoffman - Director

Derivative

Stock Option (right to buy)

7,040

-^{footnote F4}

Footnote F2 (price, shares): At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual… Full note on SEC EDGAR
Footnote F3 (price, shares): Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with… Full note on SEC EDGAR
Footnote F4 (price): At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such… Full note on SEC EDGAR

Jul 13, 2026

J. Martin Carroll - Director

Derivative

Common Stock

177,523^{footnote F2,F3}

-^{footnote F2,F3}

Jul 13, 2026

J. Martin Carroll - Director

Derivative

Stock Option (right to buy)

21,000

-^{footnote F4}

Jul 13, 2026

J. Martin Carroll - Director

Derivative

Stock Option (right to buy)

32,500

-^{footnote F4}

Jul 13, 2026

J. Martin Carroll - Director

Derivative

Stock Option (right to buy)

44,000

-^{footnote F4}

Footnote F2 (price, shares): At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual… Full note on SEC EDGAR
Footnote F3 (price, shares): Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with… Full note on SEC EDGAR
Footnote F4 (price): At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such… Full note on SEC EDGAR

Jul 13, 2026

Jay Shepard - Director

Derivative

Common Stock

164,472^{footnote F2,F3}

-^{footnote F2,F3}

Jul 13, 2026

Jay Shepard - Director

Derivative

Stock Option (right to buy)

21,000

-^{footnote F4}

Jul 13, 2026

Jay Shepard - Director

Derivative

Stock Option (right to buy)

32,500

-^{footnote F4}

Jul 13, 2026

Jay Shepard - Director

Derivative

Stock Option (right to buy)

44,000

-^{footnote F4}

Footnote F2 (price, shares): At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual… Full note on SEC EDGAR
Footnote F3 (price, shares): Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with… Full note on SEC EDGAR
Footnote F4 (price): At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such… Full note on SEC EDGAR

Jul 13, 2026

Seth H. Z. Fischer - Director

Derivative

Common Stock

141,023^{footnote F2,F3}

-^{footnote F2,F3}

Jul 13, 2026

Seth H. Z. Fischer - Director

Derivative

Stock Option (right to buy)

21,000

-^{footnote F4}

Jul 13, 2026

Seth H. Z. Fischer - Director

Derivative

Stock Option (right to buy)

32,500

-^{footnote F4}

Jul 13, 2026

Seth H. Z. Fischer - Director

Derivative

Stock Option (right to buy)

44,000

-^{footnote F4}

Footnote F2 (price, shares): At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual… Full note on SEC EDGAR
Footnote F3 (price, shares): Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with… Full note on SEC EDGAR
Footnote F4 (price): At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such… Full note on SEC EDGAR

Jul 13, 2026

John Craig Thompson - Director

Derivative

Common Stock

79,873^{footnote F2,F3}

-^{footnote F2,F3}

Jul 13, 2026

John Craig Thompson - Director

Derivative

Stock Option (right to buy)

40,000

-^{footnote F4}

Footnote F2 (price, shares): At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual… Full note on SEC EDGAR
Footnote F3 (price, shares): Consists of 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive… Full note on SEC EDGAR
Footnote F4 (price): At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such… Full note on SEC EDGAR

Jul 13, 2026

John B. Harlow Jr. - Officer

Derivative

Common Stock

424,536^{footnote F2,F3}

-^{footnote F2,F3}

Footnote F2 (price, shares): At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual… Full note on SEC EDGAR
Footnote F3 (price, shares): Consists of 424,536 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive… Full note on SEC EDGAR

Jul 13, 2026

Benjamin Looker - Officer

Derivative

Common Stock

667,524^{footnote F2,F3}

-^{footnote F2,F3}

Jul 13, 2026

Benjamin Looker - Officer

Derivative

Stock Option (right to buy)

150,000

-^{footnote F4}

Jul 13, 2026

Benjamin Looker - Officer

Derivative

Stock Option (right to buy)

201,000

-^{footnote F4}

Jul 13, 2026

Benjamin Looker - Officer

Derivative

Stock Option (right to buy)

269,230

-^{footnote F4}

Footnote F2 (price, shares): At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual… Full note on SEC EDGAR
Footnote F3 (price, shares): Includes 483,635 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with… Full note on SEC EDGAR
Footnote F4 (price): At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such… Full note on SEC EDGAR

Jul 13, 2026

Benjamin Halladay - Officer

Derivative

Common Stock

705,410^{footnote F2,F3,F4}

-^{footnote F2,F3}

Jul 13, 2026

Benjamin Halladay - Officer

Derivative

Stock Option (right to buy)

200,000

-^{footnote F5}

Jul 13, 2026

Benjamin Halladay - Officer

Derivative

Stock Option (right to buy)

213,000

-^{footnote F5}

Jul 13, 2026

Benjamin Halladay - Officer

Derivative

Stock Option (right to buy)

221,270

-^{footnote F5}

Footnote F2 (price, shares): At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual… Full note on SEC EDGAR
Footnote F3 (price, shares): Includes 477,191 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with… Full note on SEC EDGAR
Footnote F4 (shares): Includes 2,581 shares recently acquired in Esperion's Employee Stock Purchase Plan.
Footnote F5 (price): At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such… Full note on SEC EDGAR

Jul 13, 2026

Sheldon L. Koenig - Officer

Derivative

Common Stock

2,121,094^{footnote F2,F3,F4}

-^{footnote F2,F3}

Jul 13, 2026

Sheldon L. Koenig - Officer

Derivative

Stock Option (right to buy)

642,000

-^{footnote F5}

Jul 13, 2026

Sheldon L. Koenig - Officer

Derivative

Stock Option (right to buy

753,000

-^{footnote F5}

Jul 13, 2026

Sheldon L. Koenig - Officer

Derivative

Stock Option (right to buy)

647,460

-^{footnote F5}

Footnote F2 (price, shares): At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual… Full note on SEC EDGAR
Footnote F3 (price, shares): Includes 1,474,344 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive… Full note on SEC EDGAR
Footnote F4 (shares): Includes 1,983 shares recently acquired in Esperion's Employee Stock Purchase Plan.
Footnote F5 (price): At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such… Full note on SEC EDGAR

Jun 17, 2026

Benjamin Looker - Officer

Open-market sale

Common Stock

11,824^{footnote F1}

$3.16

$37K

Footnote F1 (shares): Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

Jun 17, 2026

Sheldon L. Koenig - Officer

Open-market sale

Common Stock

53,588^{footnote F1}

$3.16

$169K

Footnote F1 (shares): Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

Jun 17, 2026

Benjamin Halladay - Officer

Open-market sale

Common Stock

10,773^{footnote F1}

$3.16

$34K

Footnote F1 (shares): Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

May 28, 2026

John Craig Thompson - Director

Grant or award

Common Stock

79,873^{footnote F1}

$0.00

Footnote F1 (shares): The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026.

May 28, 2026

Jay Shepard - Director

Grant or award

Common Stock

79,873^{footnote F1}

$0.00

Footnote F1 (shares): The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026.

May 28, 2026

Robert E. Hoffman - Director

Grant or award

Common Stock

79,873^{footnote F1}

$0.00

Footnote F1 (shares): The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026.

May 28, 2026

Seth H. Z. Fischer - Director

Grant or award

Common Stock

79,873^{footnote F1}

$0.00

Footnote F1 (shares): The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026.

May 28, 2026

J. Martin Carroll - Director

Grant or award

Common Stock

79,873^{footnote F1}

$0.00

Footnote F1 (shares): The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026.

Mar 17, 2026

Benjamin Looker - Officer

Open-market sale

Common Stock

5,708^{footnote F1}

$2.70

$15K

Footnote F1 (shares): Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

Mar 17, 2026

Sheldon L. Koenig - Officer

Open-market sale

Common Stock

25,578^{footnote F1}

$2.72

$70K

Footnote F1 (shares): Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

Mar 17, 2026

Benjamin Halladay - Officer

Open-market sale

Common Stock

6,424^{footnote F1}

$2.71

$17K

Footnote F1 (shares): Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

Mar 13, 2026

Benjamin Looker - Officer

Grant or award

Common Stock

300,840^{footnote F1}

$0.00

Mar 13, 2026

Benjamin Looker - Officer

Grant or award

Stock Option (right to buy)

269,230

$0.00

Footnote F1 (shares): Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2026.

Mar 13, 2026

Sheldon L. Koenig - Officer

Grant or award

Common Stock

723,760^{footnote F1}

$0.00

Mar 13, 2026

Sheldon L. Koenig - Officer

Grant or award

Stock Option (right to buy)

647,460

$0.00

Footnote F1 (shares): Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2026.

Mar 13, 2026

Benjamin Halladay - Officer

Grant or award

Common Stock

247,430^{footnote F1}

$0.00

Mar 13, 2026

Benjamin Halladay - Officer

Grant or award

Stock Option (right to buy)

221,270

$0.00

Footnote F1 (shares): Such award will vest over a four (4) year period in equal quarterly installments, the first of which will be June 15, 2026.

Jan 20, 2026

Benjamin Looker - Officer

Open-market sale

Common Stock

1,689^{footnote F1}

$2.88

$5K

Footnote F1 (shares): Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

Oct 17, 2025

Benjamin Looker - Officer

Open-market sale

Common Stock

1,248^{footnote F1}

$2.62

$3K

Footnote F1 (shares): Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

Sep 17, 2025

Benjamin Halladay - Officer

Open-market sale

Common Stock

7,046

$2.81

$20K

Sep 17, 2025

Benjamin Looker - Officer

Open-market sale

Common Stock

6,267

$2.80

$18K

Sep 17, 2025

Sheldon L. Koenig - Officer

Open-market sale

Common Stock

28,427

$2.79

$79K

Jul 17, 2025

Benjamin Looker - Officer

Open-market sale

Common Stock

1,304

$1.13

$1K

Jul 17, 2025

Benjamin Halladay - Officer

Open-market sale

Common Stock

$1.12

$12

Filed

Filer

Relationship

Market value

Notice

Jun 17, 2026

View on EDGAR

Jun 17, 2026